康寧傑瑞製藥-B(09966.HK)續訂租賃協議
格隆匯1月3日丨康寧傑瑞製藥-B(09966.HK)公吿,由於現有租賃協議將於2021年12月31日屆滿,江蘇康寧傑瑞(作為承租人)已與蘇州康寧傑瑞(作為出租人)就租賃物業訂立一份續訂租賃協議,期限自2022年1月1日起至2024年3月31日止。
該等物業的總建築面積約為2,235平方米,位於中國江蘇省蘇州市星湖街218號生物納米園C23樓四層及五層,乃租賃自獨立第三方蘇州工業園區百諾資產營運管理有限公司(前稱蘇州工業園區生物產業發展有限公司)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.